Enliven Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ELVN$51.55+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| As of | As of | |
|---|---|---|
| September 30, 2024 | December 31, 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $100,621 | $100,141 |
| Marketable securities | 191,213 | 153,007 |
| Restricted cash | 54 | 54 |
| Prepaid expenses and other current assets | 5,109 | 2,949 |
| Contingent value right asset | — | 10,000 |
| Total current assets | 296,997 | 266,151 |
| Property and equipment, net | 549 | 742 |
| Operating lease right-of-use assets | 81 | 320 |
| Deferred offering costs | 563 | 563 |
| Other long-term assets | 7,240 | 4,091 |
| Total assets | $305,430 | $271,867 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,019 | $532 |
| Accrued expenses and other current liabilities | 16,008 | 15,362 |
| Contingent value right liability | — | 10,000 |
| Total current liabilities | 17,027 | 25,894 |
| Long-term liabilities | — | 67 |
| Total liabilities | 17,027 | 25,961 |
| Commitments and contingencies (Note 9) | ||
| Stockholders' equity: | ||
| Preferred stock, par value $0.001; authorized shares - 10,000,000; issued and outstanding shares - none | — | — |
| Common stock, par value $0.001; authorized shares - 100,000,000; issued and outstanding shares - 47,254,280 and 41,292,027 at September 30, 2024 and December 31, 2023, respectively | 47 | 41 |
| Additional paid-in capital | 508,406 | 400,172 |
| Accumulated other comprehensive income | 242 | 141 |
| Accumulated deficit | (220,292) | (154,448) |
| Total stockholders’ equity | 288,403 | 245,906 |
| Total liabilities and stockholders' equity | $305,430 | $271,867 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.